<DOC>
	<DOCNO>NCT01244789</DOCNO>
	<brief_summary>Patients stage 1 &amp; 2 endometrial cancer treat surgery . Despite fact disease confound uterus , unfortunately patient may relapse die disease . Postoperative radiotherapy improve survival . Chemotherapy show survival benefit advance stage disease ( stage 3 &amp; 4 ) . This study evaluate one improve survival intermediate high risk early-stage patient offer postoperative chemotherapy . This randomized phase 3 trial effect postoperative chemotherapy compare postoperative observation alone ( standard strategy ) . Substudy : Translational research</brief_summary>
	<brief_title>Chemotherapy Observation Stage I-II Intermediate High Risk Endometrial Cancer</brief_title>
	<detailed_description>Patients medium high risk stage I II endometrial cancer , despite radical surgery , rather high risk progression . Adjuvant radiotherapy traditional therapy many decade . Four randomized phase III study meta-analysis reveal adjuvant radiotherapy improve local control cost excessive short long term toxicity , though absolutely impact survival . Two phase III study randomize adjuvant radiotherapy versus adjuvant chemotherapy , fail show difference survival radiotherapy chemotherapy , though study criticize inferior chemotherapy regimens inclusion good prognosis patient . The GOG-122 study advance case ( stage 3 &amp; 4 ) randomize combination chemotherapy versus whole abdominal irradiation find significant improvement survival chemotherapy arm . NSGO-EC-9501 MaNGO study indicate adjuvant chemotherapy add adjuvant radiotherapy may improve survival compare adjuvant radiotherapy alone early stage medium high risk patient . One may conclude impact survival come chemotherapy . Many investigator therefore adapt adjuvant chemotherapy standard treatment various country include Denmark . However , conclusion low level evidence , randomize phase III study compare postoperative observation alone versus adjuvant chemotherapy . It utmost importance demonstrate efficacy adjuvant combination chemotherapy randomize phase III trial compare treatment medium high risk node negative stage 1 &amp; 2 patient . Combination chemotherapy regimen paclitaxel-carboplatin propose study , combination effective well tolerate . The eligible patient study fraction patient endometrial cancer therefore study perform within ENGOT collaboration .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Target Population 1 . Only nodenegative patient eligible : Histological confirm endometrial carcinoma macroscopic remain tumour primary surgery lymphnode negative disease , one follow postoperative FIGO 2009 stage grade : 1 . Stage I grade 3 endometrioid adenocarcinoma 2 . Stage II endometrioid adenocarcinoma 3 . Stage I II type 2 histology ( clear cell , serous , squamous cell carcinoma , undifferentiated carcinoma ) Prior therapy 2 . Patients undergone hysterectomy ( total abdominal hysterectomy , radical hysterectomy , laparoscopic robotic hysterectomy ) bilateral salpingooophorectomy ( BSO ) pelvic lymphadenectomy ( LNE ) . 3 . LNE : minimum 12 pelvic node ( 6 side ) remove . Paraaortic LNE optional 4 . Omentectomy strongly recommend clear cell , serous undifferentiated carcinoma . 5 . Surgery perform within 10 week randomization . If date hysterectomy lymph node dissection different , 10 week count last surgery , case gap two surgery exceed 8 week . Other inclusion criterion 6 . Patients must give informed consent accord rule regulation individual participate centre 7 . Patients receive anticancer therapy surgery . 8 . Adjuvant vaginal brachytherapy permit arm . In chemotherapy arm , time VBT cause delay chemotherapy delivery . 9 . Patients must WHO performance status 02 10 . Patients must adequate bonemarrow , renal hepatic function ( WBC ≥3.0x109/L , neutrophils ≥1.5x109/L , platelets ≥100x109/L , total Sbilirubin &lt; 2 x upper normal value , ALAT &lt; 2.5 x upper normal value , estimate GFR &gt; 50 ml/min ( measure calculate accord CockroftGault Jeliffe ) . Up 5 % deviation hematological value 10 % deviation sbilirubin ALAT tolerate . 11 . Life expectancy least 12 week 12 . Patients must fit receive combination chemotherapy 13 . Patient 's age &gt; 18 year Exclusion criterion : Target Disease Exceptions 1 . Carcinosarcoma , Sarcomas small cell carcinoma neuroendocrine differentiation . Prohibited Treatments and/or Therapies 2 . External Beam Radiotherapy 3 . Concurrent cancer therapy 4 . Concurrent treatment anticancer investigational agent participation another anticancer clinical trial Other exclusion criterion 5 . Previous concurrent malignant disease except curatively treat carcinoma situ cervix basal cell carcinoma skin 6 . Active infection serious underlie medical condition , might prevent patient receive treatment follow 7 . Whatever reason interfere adequate followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>endometrial cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Stage 1 &amp; 2</keyword>
	<keyword>node-negative</keyword>
	<keyword>intermediate risk</keyword>
	<keyword>high risk</keyword>
</DOC>